

REMARKS:

Summary of Claim Amendments and Pending Claims

Upon entry of the present amendment, claim 1 is amended; claims 2- 20 are canceled without prejudice or disclaimer. No new matter is added.

The originally filed specification and claims support the present amendments. By entry of the present amendment, claim 1 is pending and at issue and is an independent claims.

Applicants reserve the right to file continuation and/or divisional applications directed to subject matter canceled in claims 2 - 20.

This amendment is being filed for the purpose of simplifying issues on appeal and applicants respectfully request that the Examiner enter this amendment.

Conclusion

In view of the above, Applicants submit that the application is now in condition for allowance and issue and respectfully request early action to that end. Applicants believe that no additional fees are due. However, should any fees be due, the Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The undersigned invites the Examiner to contact him/her by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: March 2, 2009

/Marc A. Began, Reg. No. 48,829/

Marc A. Began, Reg. No. 48,829

Novo Nordisk Inc.

Customer Number 23650

(609) 987-5800